Greg Elson

This inventor holds 36 USPTO granted patents and 9 published patent applications, plus 8 CIPO patents and 8 EPO patents, primarily in Antibody Engineering. Top assignees: Novimmune Sa, Novimmunie S.a.. Active years: 2007-2023.

USPTO Granted Patents = 36 (Patent Applications = 9)

% Patents Active = 100.0

CIPO Patents = 8 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 2.7

ph-index = 7

Forward Citations = 342(Granted Patents)

Location History:

Collenges sous Saleve, FR (2013)
Collonges sous Saleve, FR (2007 - 2023)

Company Filing History:

Years Active: 2007-2023

Loading Chart...

Areas of Expertise:

Anti-IL-6 Antibodies

TLR4 Antibodies

Neutralizing Antibodies

Multispecific Antibodies

Autoimmune Diseases

Fc Receptor-binding Polypeptides

Diagnosis Compositions

Chimeric Polypeptides

Antibody Purification

Effector Functions

Biomarkers

CD3 Antibodies

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11613582 - Anti-IL-6/IL-6R antibodies and methods of use thereof (2023-03-28),

2. 10982004 - Anti-TLR4 antibodies and uses thereof (2021-04-20),

3. 10844132 - Neutralizing antibodies and methods of use thereof (2020-11-24),

4. 10759862 - Anti-IL-6/IL-6R antibodies and methods of use thereof (2020-09-01),

5. 10759858 - Anti-CD3 antibodies and methods of use thereof (2020-09-01),

6. 10689441 - Anti—TLR4 antibodies and methods of use thereof (2020-06-23),

7. 10597465 - Methods for the generation of multispecific and multivalent antibodies (2020-03-24),

8. 10556960 - Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers (2020-02-11),

9. 10400044 - Anti-TLR4 antibodies and uses thereof (2019-09-03),

10. 10047144 - Methods of purifying antibodies (2018-08-14),

11. 10023646 - Neutralizing antibodies and methods of use thereof (2018-07-17),

12. 9926382 - Methods for the generation of multispecific and multivalent antibodies (2018-03-27),

13. 9850304 - Anti-CD3 antibodies and methods of use thereof (2017-12-26),

14. 9834615 - Methods for the generation of multispecific and multivalent antibodies (2017-12-05),

15. 9828430 - Anti-IL-6/IL-6R antibodies (2017-11-28),

Title: The Innovative Contributions of Greg Elson in Monoclonal Antibody Development

Introduction

Greg Elson is a prominent inventor and researcher based in Collonges sous Saleve, France. With a remarkable portfolio of 36 patents, his work primarily focuses on the development of monoclonal antibodies aimed at therapeutic, diagnostic, and prophylactic applications. His innovative contributions have had a significant impact on biomedical research and healthcare.

Latest Patents

Among Greg Elson's latest patents are two pivotal inventions:

1. **Anti-IL-6/IL-6R antibodies and methods of use thereof** - This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The methods associated with this patent highlight these monoclonal antibodies' potential use as therapeutic, diagnostic, and prophylactic agents.

2. **Anti-TLR4 antibodies and uses thereof** - This patent discloses antibodies that specifically bind to Toll-like Receptor 4 (TLR-4). It also includes methods of using these anti-TLR4 antibodies as therapeutics and diagnostic tools, showcasing their importance in treating various conditions.

Career Highlights

Greg Elson's career has been distinguished by his tenure at notable companies in the biotechnology sector, including Novimmune SA and Novimmunie S.A. His work at these organizations has contributed to advancements in the development of monoclonal antibodies, establishing him as a leader in the field.

Collaborations

Throughout his career, Greg has collaborated with esteemed colleagues, including Olivier Leger and Marie Kosco-Vilbois. These collaborations have resulted in the sharing of knowledge and expertise, further enhancing the innovations and inventions that stem from his research endeavors.

Conclusion

Greg Elson's innovative spirit and dedication to research have undeniably enriched the field of biotechnology. With numerous patents to his name, his work on monoclonal antibodies not only advances scientific understanding but also paves the way for new therapeutic solutions. As the landscape of biomedical research continues to evolve, Elson's contributions will remain integral to future innovations in the healthcare industry.